ClinVar Miner

Submissions for variant NM_000303.3(PMM2):c.368G>A (p.Arg123Gln) (rs141498002)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 13
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000254854 SCV000321928 pathogenic not provided 2021-05-21 criteria provided, single submitter clinical testing Published functional studies demonstrate that R123Q affects protein stability, causes a 40% reduction of the protein half-life and results in no residual enzyme activity (Vega et al, 2011; Yuste-Checa et al., 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 30304743, 28671287, 31115488, 28807751, 10527672, 9497260, 11715002, 11156536, 26014514, 21541725, 22012410)
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000576764 SCV000696495 pathogenic Congenital disorder of glycosylation, type Ia 2016-08-04 criteria provided, single submitter clinical testing Variant summary: The PMM2 c.368G>A (p.Arg123Gln) variant involves the alteration of a conserved nucleotide. 4/5 in silico tools predict a deleterious outcome. This variant was found in 3/28750 control chromosomes at a frequency of 0.0001043, which does not exceed the estimated maximal expected allele frequency of a pathogenic PMM2 variant (0.0055902). This variant has been reported in many CDG patients as compound heterozygotes with another pathogenic variant in trans. Functional studies showed that variant of interest led to null activity of the protein and classified the variant as one of the severe mutations. Taken together, this variant is classified as pathogenic.
Genome Diagnostics Laboratory, University Medical Center Utrecht RCV000576764 SCV000743894 pathogenic Congenital disorder of glycosylation, type Ia 2017-07-28 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000576764 SCV000782487 uncertain significance Congenital disorder of glycosylation, type Ia 2016-09-22 criteria provided, single submitter clinical testing
Invitae RCV000576764 SCV000950705 pathogenic Congenital disorder of glycosylation, type Ia 2020-10-30 criteria provided, single submitter clinical testing This sequence change replaces arginine with glutamine at codon 123 of the PMM2 protein (p.Arg123Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. This variant is present in population databases (rs141498002, ExAC 0.07%). This variant has been observed in many individuals affected with PMM2-CDG (PMID: 9497260, 21541725, 22012410,15844218). ClinVar contains an entry for this variant (Variation ID: 265255). Experimental studies have shown that this missense change reduces PMM2 enzyme activity and reduces protein stability (PMID: 21541725, 26014514). For these reasons, this variant has been classified as Pathogenic.
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000576764 SCV000993427 likely pathogenic Congenital disorder of glycosylation, type Ia 2018-08-29 criteria provided, single submitter research ACMG codes: PS3, PM2, PP3, PP5
Myriad Women's Health, Inc. RCV000576764 SCV001194243 pathogenic Congenital disorder of glycosylation, type Ia 2019-12-24 criteria provided, single submitter clinical testing NM_000303.2(PMM2):c.368G>A(R123Q) is classified as pathogenic in the context of congenital disorder of glycosylation type Ia. Sources cited for classification include the following: PMID 15844218, 11156536, 21541725, 11409861, 25497157, 17166182, 25355454 and 11715002. Classification of NM_000303.2(PMM2):c.368G>A(R123Q) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening.
Baylor Genetics RCV000576764 SCV001527206 pathogenic Congenital disorder of glycosylation, type Ia 2018-10-16 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. This variant has been previously reported as disease-causing [PMID 9497260, 22012410, 10527672, 21541725, 28807751, 26014514]
Mayo Clinic Laboratories, Mayo Clinic RCV000254854 SCV001712853 pathogenic not provided 2019-09-08 criteria provided, single submitter clinical testing PS3, PS4_Moderate, PM2, PP3, PP4
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen RCV000576764 SCV000733549 pathogenic Congenital disorder of glycosylation, type Ia no assertion criteria provided clinical testing
Natera, Inc. RCV000576764 SCV001457172 pathogenic Congenital disorder of glycosylation, type Ia 2020-09-16 no assertion criteria provided clinical testing
Biochemical Molecular Genetic Laboratory,King Abdulaziz Medical City RCV000576764 SCV001469145 pathogenic Congenital disorder of glycosylation, type Ia 2020-09-10 no assertion criteria provided clinical testing
Human Genetics - Radboudumc,Radboudumc RCV000254854 SCV001956357 pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.